The NIH definitional change on clinical trials is a regulatory loophole that could let pharma-adjacent institutions run human experiments without public registry — and almost nobody outside STAT is covering it.
The US-WHO divorce + NIH transparency rollback + AI-driven drug approval acceleration form a single arc: global health governance is fracturing at the exact moment AI can compress drug pipelines by years, creating a window where speed outpaces oversight — with massive implications for biotech valuations, emerging market health sovereignty, and who controls the next pandemic narrative.